Positions Held

• Director and consultant – Winelands Medical Research Centre (2014 – present)
• Director and principle investigator – Winelands Rheumatology Centre (2014 – present)
• Board Member – Institute of Othopaedics and Rheumatology (2022 – present)

Experience

• 2006
  – Intern – GF Jooste Hospital
• 2007
  – Community service – Shongwe Hospital
• 2008
  – Registrar – Helen Joseph, Charolette Maxeke Academic and Chris Hani Baragwanath Academic Hospitals (Jan 2008 – Dec 2011)
• 2012
  – Internal Medicine Consultant and Rheumatology fellow – Chris Hani Baragwanath Academic Hospital (Jan 2012 – Dec 2013)
• 2012
  – Private Locum Wilgeheuwel Flora Hospital (Jan 2012 – Dec 2013)
• 2014
  – Specialist Physician/Rheumatologist – Winelands Rheumatology Centre (Jan 2014 – present)
• 2014
  – Consultant – Out-reach hospital (Helderberg Hospita) (Jan 2014 – present)
• 2017
  – Council of Medical Schemes (CMS) – Specialist Advisory Panel – Rheumatology division (Jan 2017 – present)
• 2018
  – Founding member and Director – Winelands Musculoskeletal Support Group (Jan 2018 – present)
• 2019
  – Research Fellow – Department of Physiological Sciences (Mar 2019 – Dec 2021)
• 2019
  – Rheumatologist – Institute of Othopaedics and Rheumatology (Aug 2019 – present)
• 2019
  – Treasurer and member of executive board – outh African Rheumatology Arthritis Association (SARAA) (2019 – 2022)
• 2021
  – Attending Physician – British and Irish Lions during their tour in 2021 (2021)

• Burch Vc, Tarr GS, Morroni C. Modified early warning score predicts the need for hospital admission and in hospital mortality. Emerg Med J. 2008 Oct;25(10):674-8
• Tarr GS, Tikly M, Makda M, Musenga ES. Impact of HIV infection on Rheumatoid Arthritis. The Journal of Rheumatology 2014; 41:8.
• Tarr GS, Hodkinson B, Reuter H. Superheroes in autoimmune warfare: Biologic therapies in current South African practice. SAMJ 2014 Nov; 104(11): 787-91.
• Tarr, GS, Reuter H. Review of the safety of nonsteroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors. South African Family Practice 2015; 57(3):18-22.
• Matatiele P, Tarr G, et al. DNA methylation similarities in genes of black South Africans with systemic lupus erythematosus and systemic sclerosis. Journal of Biomedical Science (2015) 22:34.
• Tarr, GS. All Small Molecule. Spondylo Matters. 2019; 2(1): 11-13.
• E.F. Morand, et al, for the TULIP-2 Trial Investigators*. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. NEJM; DOI: 10.1056/NEJMoa1912196.
• Bezuidenhout JA, Tarr GS, et al. Detection of Citrullinated Fibrin in Plasma Clots of Rheumatoid Arthritis Patients and Its Relation to Altered Structural Clot Properties, Disease-Related Inflammation and Prothrombotic Tendency. Front. Immunol. 04 December 2020.
• Solomon,A, Tarr GS et al. Points to consider in cardiovascular disease risk management among patients with rheumatoid arthritis living in South Africa, an unequal middle income country. BMC Rheumatol 2020 Jun 16;4:42
• Visser, MJE, Tarr GS, et al. Thrombosis in Psoriasis: Cutaneous Cytokine Production as a Potential Driving Force of Haemostatic Dysregulation and Subsequent Cardiovascular Risk. Frontiers in Immunology, section Inflammation (in print).
  Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Results from the Phase 3, Randomized, Double-blind KEEPsAKE 2 Trial for csDMARD-IR and Bio-IR Patients”. e-poster at EADV 2021.
• Strong J, Tarr GS, Et al. Development of active tuberculosis in patients treated with biologic disease modifying anti-rheumatic drugs. S Afr Med J 2022;112(2):76-80
• Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, ORAL Surveillance Investigators. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 2022; 386(4):316-326. doi: 10.1056/NEJMoa2109927.
• Ollewagen T, Tarr GS, et al. Therapeutic Benefit in Rheumatoid Cachexia Illustrated Using a Novel Primary Human Triple Cell Coculture Model. International Journal of Inflammation, vol. 2022, Article ID 1524913, 14 pages, 2022.
• Tarr GS, Mann T, Reuter H, Hodkinson B. Safety of disease-modifying anti-rheumatic drugs in spondyloarthritis: a retrospective review from a South African rheumatology centre. EULAR 2023 Abstract. AB0963.

• 2014 Winelands GP Congress (Stellenbosch) – Title: Rheumatoid Arthritis
• 2014 MediClinic GP Meeting (Stellenbosch) – Title: Updated Review of Gout Management
• 2015 Hermanus GP Invitation – Title: Updated Review of Gout Management
• 2016 GP Congress – Title: Biologic Drugs, an introduction.
• 2016 Qualicare CP Congress (George) – Title: Updated review of Gout Management
• 2016 Qualicare GP Congress (Cape Town) – Title: Updated Review of Gout Management
• 2017 Qualicare GP Congress (Cape Town) – Title: Auto-immunity, Biologic’s and everything in between.
• 2017 George GP invitation – Title: Auto-immunity, Biologic’s and everything in between.
• 2017 PCMA meeting – Title: The Future of Rheumatoid Arthritis in the Era of Biologics.
• 2019 SARAA Meeting – Title: Cancer immunotherapy and Rheumatic conditions.
• 2021 PTCMA meeting – Title: Prioritising Remission as the “New” Treatment Target in Immunology
• 2021 PTCMA meeting – Title: Advances in the management of rheumatoid arthritis
• 2022 Medi-Clinic GP Congress – Title: Delay to Diagnosis
• 2022 SpA SA Meeting – Title: Axial Spondylarthritis Awareness Seminar
• 2023 BosVeld University – Title: Medicinal Cannabis

• Randomised, Double-Blind study comparing Risankizumab to Placebo in Subjects with  Active Psoriatic Arthritis Including those who have a history of Inadequate Response or Intolerance to Biologic Therapy(ies) Protocol Number: M16-011
• A Randomised, Double-blind study Comparing Risankizumab to Placebo in subjects with Active Psoriatic Arthritis who have a history of Inadequate Response to or Intolerance to at least one disease modifying Anti-Rheumatic Drug Therapy. Protocol Number: 201790
• A 52 week multicentre, randomised, double-blind, efficacy and safety study comparing GSK3196165 with placebo and with Tofacitinib, in combination with MTX in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to MTX. Protocol Number:  209564
• A multi-centre long-term extension study to assess the safety and efficacy of GSK 3196165 in the treatment of rheumatoid arthritis
• A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis.
• Medically Ill patient assessment of Rivaroxaban versus Placebo in reducing post discharge venous Thrombo-embolism risk.
• Evaluate the Long Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease Modifying Antirheumatic Drug–Naive Patients with Active Psoriatic.
• A Multicenter Double-Blind, Randomized Controlled Study of Etanercept and  Methotrexate in combination or as Monotherapy in Subjects With Psoriatic Arthritis.
• Randomized, Safety Endpoint study of 2 doses of Tofacitinib in comparison to a TNF inhibitor in subjects with Rheumatoid Arthritis.
• Phase 2 study, Multicenter, OLE study in Rheumatoid Arthritis subjects who have completed a preceding phase 2 randomized controlled trials with ABT- 494.
• A Phase 3b, Randomized, Controlled Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination with Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults with Early Rheumatoid Arthritis who are Methotrexate Naïve.
• A Placebo-controlled, Phase 3 Extension Study to characterise the long term safety and tolerability of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus
• A Randomised, Double-Blind study comparing ABT-494 to placebo and to Adalimumab in subjects with moderately to severely active Rheumatoid Arthritis who are on a stable background of MTX and who have an Inadequate response to MTX ( MTX-IR).
• A Randomised, Double-Blind study comparing ABT-494 to placebo in subjects with moderately to severely active Rheumatoid Arthritis who are on a stable dose of csDMARDs and have had an inadequate response to csDMARDs
• A Randomized, Double-Blind Study comparing ABT-494 Dose A Once Daily Monotherapy and ABT-494 Dose Daily Monotherapy to Methotrexate(MTX) Monotherapy in MTX-Naïve Subjects with Moderately to Severely Active Rheumatoid Arthritis.
• A Randomised, controlled Double-blind Study comparing the Efficacy and Safety of Orelvo with pacebo in achieveing Renal Response in Subjects with Active Lupus Nephritis.
• A 52-week multi-center, randomized, open-label, parallel-group study evaluating the efficacy and safety of Ixekizumab versus Adalimumab in patients with Psoriatic Arthritis who are Biologic disease-modifying anti- rheumatic drug naive.
• A Randomised, Double-Blind, study comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in subjects with active Psoriatic Arthritis who have a history of inadequate response to at least one Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)-SELECT-PsA 1.
• A Randomized, Double-blind Study in Subjects with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Subjects with an Inadequate Response to Methotrexate.
• A multicentre, Double-blind, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis.
• A Randomised, controlled Double-blind, Continuation Study comparing the Long-term Safety and Efficacy of Orelvo with placebo in Subjects with Lupus Nephritis.
• A Multicentre, Randomised, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects with Active Systemic Lupus Erythematosus.
• A multi-center, uncontrolled extension study evaluating efficacy and safety of SAR153191 on top of DMARDs in patients with active Rheumatoid Arthritis.
• A Long term Extention Study of Lesinurad in Combination with Allopurinol for Subjects completing an Efficacy and Safety Study of Lesinurad and Allopurinol.
• A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment with Disease-Modifying Antirheumatic Drugs.
• A Randomized, Double-Blind, Placebo- and active Controlled,Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy.
• A randomized, double-blinded, placebo controlled, parallel group study to evaluate the effect of SAR236553/REGN 727 on the occurrence of cardio vascular events in patients who have recently experienced an acute coronary syndrome.
• A Phase 2b, Multi-centre, Long-Term Extension Trial to Evaluate the safery and tolerability of Atacicept in Subjects with Systemic Lupus Erythematosus, who completed protocol EMR 700461-023.

Randomized, double blind study of 5 mg of Tofacitinib with and without MTX in comparison to Adalimumab with MTX in subjects with moderately to severely active Rheumatoid Arthritis.

• A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BMS-931699 vs. Placebo on a background of Limited Standard of Care in the Treatment of Subjects with Active Systemic Lupus Erythematosus.
• An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated with Fibromyalgia.
• A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus.